Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Corporation Secures $20.5 Million Debt Facility with Silicon Valley Bank
RESEARCH TRIANGLE PARK, N.C. , March 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the closing of a debt facility on February 26, 2021 , with Silicon Valley Bank , which provides Liquidia with up to $20.5 million in term loans of which the first $10.5 million was
View HTML
Toggle Summary Liquidia Corporation Announces Chief Executive Officer Transition
RESEARCH TRIANGLE PARK, N.C. , Dec. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a director of the Company, effective immediately. He succeeds Neal F.
View HTML
Toggle Summary Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer
RESEARCH TRIANGLE PARK, N.C. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately. He succeeds Steve Bariahtaris who has served as Liquidia’s interim CFO since August 2020 . Mr.
View HTML
Toggle Summary Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
CRL does not cite need for additional clinical studies CRL focuses on drug CMC and device biocompatibility   information Conference Call Scheduled for Today at 9:00a . m . ET RESEARCH TRIANGLE PARK, N.C. , Nov. 25, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.
View HTML
Toggle Summary Liquidia Closes Acquisition of RareGen
Merger   Reinforc es Company’s Commitment to Patients with PAH Paul Manning and Roger Jeffs Join Liquidia Corporation Board of Directors RESEARCH TRIANGLE PARK, N.C. , Nov. 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company
View HTML
Toggle Summary Liquidia Announces Results of Special Meeting of Stockholders
Stockholders Approve RareGen Acquisition Merger Expected to Close on   or A bout November 18 , 2020 RESEARCH TRIANGLE PARK, N.C. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and
View HTML
Toggle Summary Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal
View HTML
Toggle Summary Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- Raised $75   M illion through Underwritten Public Offering - Bolstered   and Defended LIQ861 Patent Position - Advanced Efforts in Support of the RareGen, LLC Merger and Integration - Company to Host Webcast and Conference Call Today at 8:00   a.m. ET RESEARCH TRIANGLE PARK, N.C. , Nov.
View HTML
Toggle Summary Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC
Company Determines Unsolicited Offer does not Constitute Superior Proposal RESEARCH TRIANGLE PARK, N.C , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products
View HTML
Toggle Summary Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020
Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products
View HTML